Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers
Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have found that tipifarnib showed promise in treating HNSCC tumors with mutations in the HRAS gene.